• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Coronary bypass surgery versus stenting in multivessel disease involving the proximal left anterior descending coronary artery
Conclusions In patients with multivessel disease with proximal LAD involvement, CABG is associated with lower rates of the safety composite endpoint of death, MI or stroke as compared with PCI with drug-eluting stents at 5 years of follow-up (number needed to treat=21). Trial registration number PRECOMBAT clinicaltrials.gov NCT00997828; SYNTAX: clinicaltrials.gov identifier: NCT00114972 NCT00114972.
Source: Heart - February 26, 2017 Category: Cardiology Authors: Cavalcante, R., Sotomi, Y., Zeng, Y., Lee, C. W., Ahn, J.-M., Collet, C., Tenekecioglu, E., Suwannasom, P., Onuma, Y., Park, S.-J., Serruys, P. W. Tags: Drugs: cardiovascular system, Interventional cardiology, Acute coronary syndromes, Percutaneous intervention, Epidemiology Coronary artery disease Source Type: research

Safety and efficacy of ticagrelor and clopidogrel in primary percutaneous coronary intervention
Conclusions In the subset of patients with STEMI treated with primary PCI, ticagrelor compared with clopidogrel was safe, and efficacy outcomes were consistent with the overall PLATO trial. Trial registration number NCT00391872; Results.
Source: Heart - March 22, 2016 Category: Cardiology Authors: Velders, M. A., Abtan, J., Angiolillo, D. J., Ardissino, D., Harrington, R. A., Hellkamp, A., Himmelmann, A., Husted, S., Katus, H. A., Meier, B., Schulte, P. J., Storey, R. F., Wallentin, L., Gabriel Steg, P., James, S. K., on behalf of the PLATO Investi Tags: Drugs: cardiovascular system, Interventional cardiology, Acute coronary syndromes, Percutaneous intervention, Venous thromboembolism Coronary artery disease Source Type: research

Cost-effectiveness of percutaneous coronary intervention versus bypass surgery from a Dutch perspective
Conclusions For the broad population with three-vessel or left main disease who are candidates for either CABG or PCI, we found that CABG is a clinically and economically attractive revascularisation strategy compared with DES-PCI from a Dutch healthcare perspective. The cost-effectiveness of CABG versus PCI differed according to several anatomic factors, however. The newly developed SYNTAX Score II provides enhanced prognostic discrimination in this population, and may be a useful tool to guide resource allocation as well. Trial registration number Clinical trial unique identifier: NCT00114972 (http://www.clinical-trials.gov)
Source: Heart - November 26, 2015 Category: Cardiology Authors: Osnabrugge, R. L., Magnuson, E. A., Serruys, P. W., Campos, C. M., Wang, K., van Klaveren, D., Farooq, V., Abdallah, M. S., Li, H., Vilain, K. A., Steyerberg, E. W., Morice, M.-C., Dawkins, K. D., Mohr, F. W., Kappetein, A. P., Cohen, D. J., on behalf of Tags: Health policy, Drugs: cardiovascular system, Interventional cardiology, Acute coronary syndromes, Percutaneous intervention, Epidemiology Coronary artery disease Source Type: research

Cardiovascular highlights from non-cardiology journals
Dual Antiplatelet Therapy Beyond 1-year after Percutaneous Coronary Interventions for Stable Coronary Artery Disease Results in Harm The benefit of extended dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) is uncertain. The ARTIC-Interruption Trial examined discontinuation of DAPT at 1-year after PCI vs continuation for an additional 6–18 months. The study randomized patients 1-year after PCI to continuation (N=635) or interruption (N=624) groups, and examined the primary composite endpoint of death, myocardial infarction, stent thrombosis, stroke, or urgent revascularization over a med...
Source: Heart - January 14, 2015 Category: Cardiology Authors: Bradley, S. M. Tags: Journal scan Source Type: research